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Introduction: Disseminated intravascular coagulation causes thrombotic tendency leading to multiple organ failure
and occurs in a wide variety of diseases including malignancy. Disseminated intravascular coagulation is a latent
complication in people with prostate cancer.
Case presentation: A 51-year-old Japanese man with advanced castration-resistant prostate cancer was admitted
to our hospital because of extensive purpura and severe anemia. Prolonged plasma coagulation time,
hypofibrinogenemia and normal platelet count suggested that a decrease in fibrinogen induced a bleeding
tendency causing purpura. However, elevated plasma levels of thrombin-antithrombin complex, fibrin and/or
fibrinogen degradation products and D-dimers, with positive fibrin monomer test, manifested disseminated
intravascular coagulation and subsequent fibrinolysis. Plasma levels of thrombin-antithrombin complex, fibrin and/or
fibrinogen degradation products and D-dimers decreased after administration of low-molecular-weight heparin.
However, low fibrinogen and α2-antiplasmin levels were not improved and plasmin-antiplasmin complex did not
decrease, which revealed excessive fibrinolysis complicated with disseminated intravascular coagulation. We
suspected that prostate cancer cell-derived urokinase-type plasminogen activator caused excessive fibrinolysis.
Administration of tranexamic acid for fibrinogenolysis was added together with high-dose anti-androgen therapy
(fosfestrol) for prostate cancer. Thereafter, prostate-specific antigen and plasmin-antiplasmin complex decreased,
followed by normalized fibrinogen and α2-antiplasmin levels, and the patient eventually recovered from the
bleeding tendency. Immunohistochemical staining of the biopsied prostate tissue exhibited that the prostate
cancer cells produced tissue factor, the coagulation initiator, and urokinase-type plasminogen activator.
Conclusion: This patient with rare complications of disseminated intravascular coagulation and excessive
fibrinolysis is a warning case of potential coagulation disorder onset in patients with prostate cancer. We propose
that combined administration of tranexamic acid and low-molecular-weight heparin together with high-dose anti-
androgen therapy is a useful therapeutic option for patients with this complicated coagulation disorder.
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Table 1 Laboratory data on the first hospitalization day
and relationship between fibrinogen, α2-antiplasmin,
D-dimers/FDP ratio, thrombin-antithrombin complex, and
plasmin-antiplasmin complex
Examination items Value Standard value
Hemoglobin (g/dL) 5.6 14.0–17.7
White blood cells (/μL) 17,400 3500–8500
Platelet (/μL) 171,000 145,000–325,000
Prothrombin time (seconds) 17.6 11.0–15.2
APTT (seconds) 48.8 32.2–42.2
Fibrinogen (mg/dL) 62 150–450
Antithrombin (%) 65 81–121
Plasminogen (%) 76 70–111
α2-antiplasmin (%) 28 88–120
FDPs (μg/mL) 161.8 <5.0
D-dimers (μg/mL) 77.1 <1.0
Fibrin monomer test Positive Negative
TAT (ng/mL) 113.78 <3.0
PAP (μg/mL) 13.98 <0.8
PSA (ng/mL) 905 <4
APTT activated partial thromboplastin time, FDPs fibrin and/or fibrinogen
degradation products LMWH low-molecular-weight heparin, PAP plasmin-
antiplasmin complex, PSA prostate-specific antigen, TAT thrombin-
antithrombin complex.
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One of the lethal complications of patients with solid
tumors is disseminated intravascular coagulation (DIC)
in which microthrombi are formed by abnormal activa-
tion of the coagulation system. Although consumption
of coagulation factors and activation of the fibrinolytic
system are always observed, severe bleeding tendency
and excessive fibrinolysis are rare in DIC. In prostate
cancer (PC), the incidence of DIC complication is from
13% to 30% whereas that of bleeding symptoms is only
0.40% to 1.65% [1]. PC cells express tissue factor (TF)
[2] that initiates the extrinsic coagulation pathway [3]
and leads to DIC [4]. Moreover, PC cells produce
urokinase-type plasminogen activator (uPA) [5] that
converts plasminogen to plasmin: a fibrinolytic protease
[6]. TF is the causative of DIC that is reported to be a
sign of metastatic PC [7]. TF and uPA are associated
with PC metastasis and angiogenesis as negative prog-
nostic factors [2,8,9]. Thus, it is possible that PC cells in-
duce simultaneously DIC by TF and fibrinolysis by uPA
in the patient, especially at the advanced stage. Little at-
tention has been paid to the potential pathogenicity of
PC cells, particularly in fibrinolysis.
In this paper, we report a patient with metastatic PC
who showed a severe bleeding tendency with hypofibri-
nogenemia by excessive fibrinolysis accompanied by
DIC. To elucidate the pathophysiology of the coagula-
tion disorder, we analyzed values of coagulation and fi-
brinolysis markers and examined the biopsied PC tissue
for TF and uPA production. Furthermore, we propose
an atypical (unusual) but appropriate treatment for such
a patient.
Case presentation
A 51-year-old Japanese man who had advanced
castration-resistant PC was admitted to our hospital
because of extensive purpura and severe anemia.
Although his platelet count was within the reference
range and plasma clotting time was slightly prolonged,
the fibrinogen level was low. Plasma levels of thrombin-
antithrombin complex (TAT), fibrin and/or fibrinogen
degradation products (FDPs), D-dimers and plasmin-
antiplasmin complex (PAP) were high. Plasma α2-anti-
plasmin (α2-AP) level was low and a fibrin monomer test
was positive (Table 1). These data indicated that he had
DIC. Plasma TAT, FDPs, and D-dimers decreased
(Figure 1) and platelet count increased after administra-
tion of low-molecular-weight heparin (LMWH). How-
ever, fibrinogen and α2-AP did not increase and PAP did
not decrease (Figure 1). Bleeding diathesis continued
whereas DIC parameters were improved by the treat-
ment. To inhibit activation of fibrinolysis, administration
of tranexamic acid was started together with LMWH.
Then, PAP level decreased and levels of α2-AP andfibrinogen increased. Bleeding tendency disappeared.
High-dose anti-androgen therapy (fosfestrol) for PC was
also performed on day 20 for PC. Prostate-specific
antigen level decreased to 482.4ng/mL.
To investigate a correlation of coagulation and fibrin-
olysis markers, we analyzed the values of 31 plasma
samples obtained during the 90-day hospitalization. As
shown in Figure 2, the patient’s fibrinogen level corre-
lated with levels of α2-AP (r
2=0.7811, P<0.0001) and
PAP (r2=0.5394, P<0.0001), and D-dimer/FDP ratio
(r2=0.6473, P<0.0001). There was no correlation between
levels of fibrinogen and TAT. The level of α2-AP
(r2=0.7060, P<0.0001) correlated positively with D-
dimer/FDP ratio and negatively with PAP level
(r2=0.5549, P<0.0001). The prostate tissue biopsied for
the initial diagnosis was immunostained using monoclo-
nal antibodies specific for human TF [10] or uPA (Fuji
chemical, Toyama, Japan). This analysis revealed that the
cancer cells were positive for both TF and uPA
(Figure 3).
Discussion
We present a patient with PC who had a bleeding
tendency of which the first sign was purpura. DIC is
initiated by TF [4] with factor VIIa that activates the
extrinsic coagulation pathway. TF is positive in more



























Figure 1 Clinical course of the patient. α2-AP: α2-antiplasmin;
FDP: fibrin and/or fibrinogen degradation product; LMWH: low-
molecular-weight heparin; PAP: plasmin-α2-antiplasmin complex;
TAT: thrombin-antithrombin complex; TX: tranexamic acid. Open
square: TAT; open circle: FDP; closed triangle: D-dimer; open
diamonds: PAP; closed circle: fibrinogen; closed square: α2-AP.
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The TF expression in the PC cells of this patient
(Figure 3) suggests DIC induction by the cancer-derived
TF. Coagulation activation results in fibrinogen con-
sumption to some extent but the severe hypofibrinogen-
emia seen in the present case is unusual in DIC [11].This was supported by no correlation between fibrino-
gen and TAT levels (Figure 2). By LMWH administra-
tion, levels of FDP, D-dimer and TAT decreased but the
fibrinogen level was not improved (Figure 1). These
results indicated that hypofibrinogenemia was not
induced by DIC alone. Under normal conditions, plas-
min degrades only stable fibrin (cross-linked fibrin) and
is immediately inhibited by α2-AP in circulation. If the
plasma α2-AP level is below 60% of the normal level, α2-
AP is unable to control plasmin sufficiently, thus plas-
min also degrades fibrinogen, fibrin monomers and un-
stable fibrin in addition to stable fibrin [12]. The high
PAP and low α2-AP levels at the hospitalization day 1
(Figure 1) indicated consumption of α2-AP by forming
complexes with increased plasmin. Plasmin generates D-
dimers only from stable fibrin, whereas FDP derives
from either fibrinogen or any forms of fibrin. Accord-
ingly, the decrease in D-dimers/FDP ratio indicated a
relative increase in fibrinogenolysis that could lead to
hypofibrinogenemia. By the treatment with tranexamic
acid, the low fibrinogen level elevated in correlation to
the increase in D-dimers/FDP ratio and α2-AP level and
to the decrease in PAP level. It is probable that the se-
vere hypofibrinogenemia in this patient was caused by
fibrinogenolysis due to excess plasmin production. The
low plasma α2-AP level and high plasma PAP level
agreed with the fibrinogenolysis observed in a patient
with metastatic PC [13]. Bleeding diathesis of this pa-
tient was improved by administration of tranexamic acid
in relation to elevation of α2-AP level, suggesting that
excessive fibrinolysis induced bleeding diathesis. Platelet
and coagulation factors, such as factor VIII and IX, are
important in normal hemostasis. From data that the
platelet count was within the normal range and clotting
time was slightly prolonged, it is unlikely that bleeding
diathesis was caused by thrombocytopenia or consump-
tion of coagulation factors. The result that fibrinolysis
activation was not improved by anticoagulation therapy
alone, suggests an involvement of the primary fibrinoly-
sis, at least partially, in the bleeding diathesis. The
plasma uPA level was not measured, but uPA expressed
in PC cells probably contributed to excessive fibrinolysis.
Unfractioned heparin has been used for treating
patients with DIC complicated with cancer and shown
to prolong their survival. Tranexamic acid inhibits
plasminogen activation, thereby causing thrombotic
tendency in typical DIC cases [14], therefore, this agent
is usually contraindicative for DIC patients. However, in
this case, together with LMWH for DIC, we adminis-
tered tranexamic acid to the patient who manifested
excessive fibrinolysis, and successfully controlled the
complicated coagulation disorder. In such a case, tranex-




Figure 2 Relationship between levels of fibrinogen, α2-antiplasmin, D-dimers/FDP ratio, thrombin-antithrombin complex, and plasmin-
antiplasmin complex. Pearson correlation coefficients (r) were used to determine the associations between the coagulation markers. α2-AP:
α2-antiplasmin; FDP: fibrin and/or fibrinogen degradation product; PAP: plasmin-α2-antiplasmin complex; TAT: thrombin-antithrombin complex.
Figure 3 Immunohistochemical staining for tissue factor (A, magnification ×200) or urokinase-type plasminogen activator
(B, magnification ×100). Arrows indicate positive cancer cells.
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A PC cell itself may often be overlooked as a causative
of coagulation disorder because of the very low inci-
dence of overt DIC in PC [1]. Even if a clinician notices
DIC in such a patient, he or she may erroneously con-
sider that any changes of coagulation markers are caused
solely by DIC. Accordingly, such a patient may receive
only heparin infusion, which would not adequately meet
the patient’s bleeding tendency accompanied by exces-
sive fibrinolysis induced by uPA secreted from PC cells.
Although it is widely known that uPA plays important
roles in PC cell invasion and proliferation [9,15], the
classical aspect of uPA as an activator of the fibrinolytic
system may paradoxically not be easily conceivable in
patients with PC with bleeding disorder. Therefore, it is
important to bear in mind that PC cell uPA can generate
plasmin that degrades fibrinogen, leading to hypofibrino-
genemia and resultant bleeding tendency. The present
case of a rare complication of excessive fibrinolysis raises
awareness of a potential fibrinolytic system being acti-
vated in patients with PC. Hence, we hereby propose the
treatment of combined administration of tranexamic
acid and LMWH together with high-dose anti-androgen
therapy for a patient with PC with fibrinolysis coincident
with DIC.
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